ArTS Archivio della ricerca di Trieste

ZAJA, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.304
AS - Asia 8.431
EU - Europa 5.933
SA - Sud America 1.343
AF - Africa 319
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 4
Totale 30.352
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.044
SG - Singapore 3.372
CN - Cina 1.465
PL - Polonia 1.246
HK - Hong Kong 1.152
BR - Brasile 1.026
IT - Italia 1.013
SE - Svezia 899
VN - Vietnam 884
DE - Germania 497
FR - Francia 470
KR - Corea 424
RU - Federazione Russa 375
BD - Bangladesh 349
BG - Bulgaria 274
IE - Irlanda 273
IN - India 227
GB - Regno Unito 208
FI - Finlandia 200
MA - Marocco 137
CA - Canada 136
NL - Olanda 119
AR - Argentina 111
TR - Turchia 81
JP - Giappone 72
ES - Italia 69
UA - Ucraina 69
MX - Messico 65
EC - Ecuador 63
ID - Indonesia 56
ZA - Sudafrica 53
AT - Austria 47
IQ - Iraq 45
PK - Pakistan 40
CH - Svizzera 36
CO - Colombia 28
CZ - Repubblica Ceca 28
SN - Senegal 27
IL - Israele 26
PY - Paraguay 26
SA - Arabia Saudita 26
UZ - Uzbekistan 25
VE - Venezuela 25
CL - Cile 24
BE - Belgio 23
EG - Egitto 21
PH - Filippine 21
JO - Giordania 19
AU - Australia 17
AE - Emirati Arabi Uniti 15
DZ - Algeria 15
TN - Tunisia 15
BO - Bolivia 14
KE - Kenya 14
MY - Malesia 13
NP - Nepal 13
LT - Lituania 12
PE - Perù 12
RO - Romania 12
UY - Uruguay 12
CR - Costa Rica 11
IR - Iran 10
TW - Taiwan 10
DO - Repubblica Dominicana 9
HR - Croazia 9
TH - Thailandia 9
AZ - Azerbaigian 8
JM - Giamaica 8
KZ - Kazakistan 8
TT - Trinidad e Tobago 8
AO - Angola 7
ET - Etiopia 7
HU - Ungheria 7
KG - Kirghizistan 7
LK - Sri Lanka 7
NO - Norvegia 7
OM - Oman 7
CI - Costa d'Avorio 6
BB - Barbados 5
HN - Honduras 5
LB - Libano 5
LV - Lettonia 5
RS - Serbia 5
SK - Slovacchia (Repubblica Slovacca) 5
BA - Bosnia-Erzegovina 4
DK - Danimarca 4
GR - Grecia 4
LA - Repubblica Popolare Democratica del Laos 4
MN - Mongolia 4
SY - Repubblica araba siriana 4
AM - Armenia 3
BH - Bahrain 3
GA - Gabon 3
GE - Georgia 3
KW - Kuwait 3
PT - Portogallo 3
SI - Slovenia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BW - Botswana 2
EE - Estonia 2
Totale 30.306
Salva come PNG Salva come JPEG
Città #
Singapore 2.246
Ashburn 1.782
Fairfield 1.597
Hong Kong 1.141
San Jose 976
Warsaw 952
Woodbridge 769
Houston 671
Seattle 669
Wilmington 616
Chandler 596
Cambridge 517
Princeton 478
Boardman 426
Beijing 417
Seoul 416
Santa Clara 330
Chicago 302
Ho Chi Minh City 296
Ann Arbor 290
Columbus 270
Sofia 270
Dublin 268
Lauterbourg 264
Zgierz 262
Jacksonville 246
Munich 240
Hefei 229
Trieste 201
Hanoi 175
The Dalles 168
Milan 163
Moscow 157
Council Bluffs 156
Los Angeles 154
Helsinki 149
Dallas 143
San Diego 129
Casablanca 113
New York 112
São Paulo 85
Frankfurt am Main 81
Buffalo 61
London 57
Montreal 43
Düsseldorf 42
Orem 41
Mumbai 40
Da Nang 38
Miano 38
Rome 38
Dong Ket 36
Norwalk 35
Tokyo 33
Memphis 32
Phoenix 31
Brooklyn 30
Chennai 29
Haiphong 29
Johannesburg 29
Nuremberg 29
San Francisco 29
Toronto 29
Guangzhou 28
Tianjin 28
Nanjing 27
Vienna 27
Dakar 26
Shanghai 26
Stockholm 26
Atlanta 25
Boston 25
Redondo Beach 25
Redwood City 25
Washington 25
Belo Horizonte 23
Rio de Janeiro 23
Campinas 22
Bern 21
Bremen 21
Quito 21
Tashkent 21
Curitiba 19
Jinan 19
Brasília 18
Brno 18
Brussels 18
Mexico City 18
Poplar 18
Turku 18
Baghdad 17
Dearborn 17
Denver 17
Dhaka 17
Hải Dương 17
Istanbul 17
Lappeenranta 17
Manchester 17
Santiago 17
Amman 16
Totale 21.071
Salva come PNG Salva come JPEG
Nome #
KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival 474
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: Evidence for a NOTCH1 mutation-driven epigenetic dysregulation 403
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines 379
Mutations in the 3' untranslated region (3' UTR) of NOTCH1 are associated with low CD20 expression levels in chronic lymphocytic leukemia 345
Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations 337
NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components 248
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. 245
CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. 236
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience 232
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials 210
Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT) 208
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia 202
The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study 191
Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations 190
TP53 mutations with low variant allele frequency predict short survival in Chronic Lymphocytic Leukemia 190
The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells 187
Evolving trends in epidemiology and natural history of cardiac amyloidosis: 30-year experience from a tertiary referral center for cardiomyopathies 183
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned 181
Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection 180
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 179
Efficacy and safety of rituximab in type II mixed cryoglobulinemia 178
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 178
Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review 178
Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands? 177
Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation 177
Low-dose rituximab in adult patients with primary immune thrombocytopenia 175
Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice 173
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis 173
Preventive versus curative photobiomodulation for oral mucositis in patients with multiple myeloma undergoing hematopoietic stem cell transplantation: which approach is more effective? 171
CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. 166
Rituximab in the treatment of immune thrombocytopenia: What is the role of this agent in 2019? 164
Efficacy of selective B cell Blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells 163
Bendamustine salvage therapy for T cell neoplasms 162
A case report of isolated cardiac light chain amyloidosis without clinically overt heart failure: an under-recognized presentation 160
Acute hepatic failure as onset of progressive sclerodermatous chronic graft-versus-host disease after donor lymphocyte infusion 160
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia 160
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 159
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia 159
Mycophenolate Mofetil for Immune Thrombocytopenia. Reply 159
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response 158
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 158
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi 158
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 156
Rituximab for the treatment of type II mixed cryoglobulinemia 156
CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma 156
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia 156
B-cell compartment as the selective target for the treatment of immune thrombocytopenias 155
Impact of clinical data on chest radiography sensitivity in detecting pulmonary abnormalities in immunocompromised patients with suspected pneumonia 154
The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin's lymphoma 152
Case Report: Cardiac Involvement by Lymphoma: Rare but Heterogeneous Condition With Challenging Behaviors 152
B-cell depletion with rituximab as treatment for autoimmune thrombocytopenia 151
Autologous stem cell transplantation for Hodgkin's lymphoma: results and prognostic factors in 51 high-risk patients 151
Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab 150
Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant 150
Management of immune thrombocytopenia in elderly patients 148
Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma 148
Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia 147
153) LAPAROSCOPIC SPLENECTOMY FOR MASSIVELY ENLARGED SPLEENS: TECHNICAL ASPECTS AND RESULTS OF 8 CONSECUTIVE CASES 144
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters 143
MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL) 142
Updated international consensus report on the investigation and management of primary immune thrombocytopenia 142
Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma 141
Immune thrombocytopenia 141
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 139
Surgical staging in Hodgkin's disease: the role of laparoscopic splenectomy 138
Registries in immune thrombocytopenia (ITP) in Europe: the European Research Consortium on ITP (ERCI) network 137
T-cell chimerism and clinical outcome after reduced-intensity conditioning allogeneic stem cell transplantation 137
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 136
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers 135
CD49d promotes disease progression in chronic lymphocytic leukemia: New insights from CD49d bimodal expression 135
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL 135
Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma 134
Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: The emerging therapeutic role of casirivimab/imdevimab 133
Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study 133
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial 131
SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation 131
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi 130
A retrospective analysis of 144 patients with aggressive non-Hodgkin's lymphoma: impact of aurtologoaus stem cell transplantation in first remission on autcome 129
NOTCH1 mutational status in chronic lymphocytic leukaemia: Clinical relevance of subclonal mutations and mutation types 128
Rituximab in a case of cold agglutinin disease 127
Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation 127
CD38, BCL-2, PD-1 and PD-1L expression in nodal peripheral T-cell lymphoma (PTCL): Possible biomarkers for novel targeted therapies? 127
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study 125
Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi 125
Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma 124
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 124
Hepatitis C virus infection among cryoglobulinemic and non-cryoglobulinemic B-cell non-Hodgkin’s lymphomas 124
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine 124
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia 123
KERATOCONJUNCTIVITIS TREATMENT WITH AUTOLOGOUS SERUM EYE IN PATIENTS WITH SEVERE CHRONIC GVHD 123
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 121
Clinical features and outcome of multiple myeloma arising from the transformation of a monoclonal gammapathy of undetermined significance 121
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study 121
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 120
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia 120
High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome 119
NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: Link between the NOTCH1 and the NF-κ B pathways 119
Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot study 118
Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice 116
Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas 116
Totale 16.506
Salva come PNG Salva come JPEG
Categoria #
all - tutte 114.090
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 114.090
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021451 0 0 0 0 0 0 0 0 0 0 0 451
2021/20222.370 57 269 64 240 18 77 169 109 312 234 108 713
2022/20232.377 304 268 241 177 246 473 10 225 270 39 89 35
2023/20241.983 87 75 142 51 83 217 335 626 46 36 129 156
2024/20255.983 48 864 946 412 385 461 390 322 536 560 429 630
2025/202611.347 934 441 651 1.105 905 874 1.607 431 1.260 1.856 721 562
Totale 31.194